Phase III CAMELLIA-TIMI CVOT for Belviq ongoing

Eisai Co. Ltd. (Tokyo:4523, Tokyo, Japan) said an independent DMC recommended continuation of the Phase IIIb/IV CAMELLIA-TIMI 61 cardiovascular outcomes trial of Belviq lorcaserin (APD356) for chronic weight management. The DMC based its recommendation on a pre-specified interim safety analysis evaluating the incidence of major adverse cardiovascular events (MACE), comprising myocardial infarction (MI), stroke and cardiovascular (CV) death.

The double-blind, placebo-controlled, international trial is evaluating 10 mg oral Belviq twice daily for 5 years in 12,000 patients with a BMI of ≥27 kg/m² and CV disease or CV risk factors...